Lamivudine Lamivudine/AZT

Usual Dosing (Adults)

HIV: 150mg po q12h or 300mg po qd.
Hepatitis B (Epivir-HBV ®): 100mg po qd.

Combivir ®: [150mg lamivudine/ 300mg AZT]: 1 tablet bid.

Renal Dosing

Lamivudine-Epivir ®:
HIV:
[CRCL > 50]: No changes
[30-49]: 150mg po qd.
[15-29]: 150mg po x 1, then 100mg po qd.
[5-14]: 150mg x 1, then 50mg qd.
[<5]: 50mg x 1, then 25mg qd.

Hepatitis B:
[CRCL > 50]: No changes
[30-49]: 100mg po x 1, then 50mg po qd.
[15-29]: 100mg po x 1, then 25mg po qd.
[5-14]: 35mg po x 1, then 15mg po qd.
[<5]: 35mg po x 1, then 10mg po qd.

-----------------
Lamivudine/Zidovudine - Combivir ®:
[CRCL >50 ml/min]: No changes.
[<50]:Give each agent separately and adjust based on respective renal dosing guidelines.

Hemodialysis

Lamivudine- Epivir ®:
HIV: 50mg x 1, then 25-50mg qd.
Hepatitis B: 35mg po x 1, then 10mg po qd.

Lamivudine/Zidovudine - Combivir ®:
Give each agent separately and adjust based on respective renal dosing guidelines.

Reference(s)

National Institutes of Health, U.S. National Library of Medicine, DailyMed Database.
Provides access to the latest drug monographs submitted to the Food and Drug Administration (FDA). Please review the latest applicable package insert for additional information and possible updates. A local search option of this data can be found here.